Transgene

Transgene Rule of 40

The Rule of 40 of Transgene (TNG.PA) as of Nov 18, 2026 is -606.68 %. In the previous year, Rule of 40 was -416.81 % — a change of 45.55% (lower).

Rule of 40

-606.68 %

YoY

45.55%

Last updated:

Rule of 40 of Transgene is 2024 -606.68 % . Rule of 40 of Transgene was 2023 -416.81 % . It decreases by 45.55% lower compared to the previous year.

The Transgene Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2017
-389.86 EUR
Jan 1, 2018
99.29 EUR
Jan 1, 2019
-103.31 EUR
Jan 1, 2020
-286.53 EUR
Jan 1, 2021
-56.14 EUR
Jan 1, 2022
-340.13 EUR
Jan 1, 2023
-416.81 EUR
Jan 1, 2024
-606.68 EUR
The Transgene Rule of 40 history
YEARRule of 40YoY
-606.68 %+45.55%
-416.81 %+22.54%
-340.13 %+505.86%
-56.14 %-80.41%
-286.53 %+177.36%
-103.31 %-204.05%
99.29 %-125.47%
-389.86 %+46.76%
-265.64 %-14.11%
-309.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Rule of 40 of Transgene is -606.68 % in 2024.

On Eulerpool you can find the complete historical development of Rule of 40 Transgene since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Transgene

All Key Metrics — Transgene